FTSE MIB
33.481,65 -234,89 (-0,70%) Dow Jones
39.169,52 +50,66 (+0,13%) Nasdaq
17.879,30 +146,70 (+0,83%) Nikkei 225
40.074,69 +443,63 (+1,12%) Petrolio
83,96 +0,58 (+0,70%) Bitcoin EUR
58.464,34 -142,93 (-0,24%)
BCDA Aug 2024 1.000 call
| Chiusura precedente | 0,1500 |
| Aperto | 0,1500 |
| Denaro | 0,0000 |
| Domanda | 0,7500 |
| Prezzo d'esercizio | 1,00 |
| Scadenza | 2024-08-16 |
| Min-Max giorno | 0,1500 - 0,1500 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 2 |
GlobeNewswireBioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II
SUNNYVALE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces completion of enrollment in its CardiAMP Heart Failure Trial and initiation of a discussion with the FDA on a second pivotal study protocol adapted for the responders in the initial trial with the objective of gaining FDA marketing approval. As previously disclosed, interim trial resu
- GlobeNewswire
BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs
SUNNYVALE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announced a clarification and next steps on its autologous CardiAMP cell therapy programs. Based on the recent interim results in the CardiAMP autologous cell therapy for the treatment of heart failure (BCDA-01), the Company is exploring development of a new Phase III clinical trial protocol.
- GlobeNewswire
BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial
SUNNYVALE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announced it has finalized external review of interim data and evaluated interim efficacy results for the ongoing Phase III pivotal trial of CardiAMP® Cell Therapy for Heart Failure (CardiAMP HF, clinicaltrials.gov Identifier: NCT02438306), for which the FDA granted Breakthrough Designation fo
